Botulinum toxin should be firstline treatment for poststroke spasticity

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 80, Issue 4, 2009, Pages 359-

  Sheean, Geoffrey ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACLOFEN; BOTULINUM TOXIN; DANTROLENE; DIAZEPAM; TIZANIDINE; ANTIPARKINSON AGENT; CENTRAL MUSCLE RELAXANT; CLONIDINE; DRUG DERIVATIVE;

ARM; COST OF ILLNESS; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; EDITORIAL; FLEXOR MUSCLE; HUMAN; LEG; PHYSIOTHERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; SOMNOLENCE; SPASTICITY; STROKE; TREATMENT OUTCOME; NOTE; PATHOPHYSIOLOGY; SURVIVOR;

ANTI-DYSKINESIA AGENTS; BOTULINUM TOXINS; CLONIDINE; HUMANS; MUSCLE RELAXANTS, CENTRAL; MUSCLE SPASTICITY; STROKE; SURVIVORS; UPPER EXTREMITY;

EID: 64749086513     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2008.164889     Document Type: Editorial

References (9)

1. Wade DT. Stroke rehabilitation and long term care. Lancet 1992;339:791-3.
2. Bamford J, Sandercock P, Dennis M, et al. A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project. 2. Incidence, case fatality rates and overall outcome at one year of cerebral infarction, primary intracerebral and subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 1990;53:16-22.
3. Watkins CL, Leathley MJ, Gregson JM, et al. Prevalence of spasticity post stroke. Clin Rehabil 2002;16:515-22.
4. Welmer AK, von Arbin M, Widén Holmqvist L, et al. Spasticity and its association with functioning and health-related quality of life 18 months after stroke. Cerebrovasc Dis 2006;21:247-53.
5. Bhakta BB, Cozens JA, Chamberlain MA, et al. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry 2000;69:217-21.
6. Ivanhoe CB, Francisco GE, McGuire JR, et al. Intrathecal baclofen management of poststroke spastic hypertonia: implications for function and quality of life. Arch Phys Med Rehabil 2006;87:1509-15.
7. Sheean GL. Botulinum treatment of spasticity: why is it so difficult to show a functional benefit? Curr Opin Neurol 2001;14:771-6.
8. Sheean G. Botulinum toxin treatment of adult spasticity: a benefit-risk assessment. Drug Saf 2006;29:31-48.
9. Simpson DM, Gracies JM, Yablon SA, et al. Botulinum neurotoxin vs tizanidine in upper limb spasticity: a placebo-controlled study. J Neurol Neurosurg Psychiatry 2009;80:380-5.